[go: up one dir, main page]

CY1108681T1 - Συνδετης αρο-2 - Google Patents

Συνδετης αρο-2

Info

Publication number
CY1108681T1
CY1108681T1 CY20081101467T CY081101467T CY1108681T1 CY 1108681 T1 CY1108681 T1 CY 1108681T1 CY 20081101467 T CY20081101467 T CY 20081101467T CY 081101467 T CY081101467 T CY 081101467T CY 1108681 T1 CY1108681 T1 CY 1108681T1
Authority
CY
Cyprus
Prior art keywords
apo
ligand
connector
apoptosis
antibodies
Prior art date
Application number
CY20081101467T
Other languages
English (en)
Inventor
Avi J Ashkenazi
Robert F Kelley
Mark T O´Connel
Robert M Pitti
Ralph H Schwall
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of CY1108681T1 publication Critical patent/CY1108681T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Παρέχεται πρωτότυπη κυτοκίνη, που ορίζεται ως συνδέτης Αρο-2, που επάγει απόπτωση καρκινικών κυττάρων θηλαστικών. Ο συνδέτης Αρο-2 πιστεύεται ότι είναι μέλος της οικογένειας κυτοκινών TNF. Παρέχονται επίσης συνθέσεις που περιλαμβάνουν χίμαιρες συνδέτη Αρο-2, νουκλεϊκά οξέα που κωδικοποιούν συνδέτη Αρο-2, και αντισώματα κατά του συνδέτη Αρο-2. Παρέχονται επιπλέον μέθοδοι χρήσης συνδέτη Αρο-2 για επαγωγή απόπτωσης και για θεραπευτική αγωγή παθολογικών καταστάσεων όπως καρκίνος.
CY20081101467T 1998-01-15 2008-12-17 Συνδετης αρο-2 CY1108681T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US788698A 1998-01-15 1998-01-15
US6053398A 1998-04-15 1998-04-15
EP99903166A EP1045906B1 (en) 1998-01-15 1999-01-15 Apo-2 ligand

Publications (1)

Publication Number Publication Date
CY1108681T1 true CY1108681T1 (el) 2014-04-09

Family

ID=26677483

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101467T CY1108681T1 (el) 1998-01-15 2008-12-17 Συνδετης αρο-2

Country Status (12)

Country Link
US (1) US6740739B1 (el)
EP (2) EP1045906B1 (el)
JP (2) JP2002508962A (el)
AT (1) ATE411385T1 (el)
AU (1) AU2325199A (el)
CA (1) CA2318029C (el)
CY (1) CY1108681T1 (el)
DE (1) DE69939732D1 (el)
DK (1) DK1045906T3 (el)
ES (1) ES2316182T3 (el)
PT (1) PT1045906E (el)
WO (1) WO1999036535A1 (el)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284236B1 (en) 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
US20040038347A1 (en) * 1996-03-14 2004-02-26 Human Genome Sciences, Inc. Apoptosis inducing molecule I
EP1873244A3 (en) * 1999-06-02 2008-04-02 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
CN100526463C (zh) * 1999-06-28 2009-08-12 杰南技术公司 利用二价金属离子制备Apo-2配体的方法
US20040186051A1 (en) * 2001-10-02 2004-09-23 Kelley Robert F Apo-2 ligand variants and uses thereof
EP2322165A1 (en) * 2001-11-13 2011-05-18 Genentech, Inc. Apo2 ligand/TRAIL formulations
US7741285B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
CN1313611C (zh) * 2002-02-22 2007-05-02 中国人民解放军第二军医大学 新型肿瘤凋亡素2配体基因、其表达的肿瘤凋亡素及其制法
AU2003247609A1 (en) * 2002-06-24 2004-01-06 Genentech, Inc. Apo-2 ligand/trail variants and uses thereof
GB0328261D0 (en) 2003-12-05 2004-01-07 Univ Groningen Improved cytokine design
US20080242603A1 (en) * 2004-02-20 2008-10-02 Yan Wang Novel Apo2L and IL-24 Polypeptides, Polynucleotides, and Methods of Their Use
AU2012200601B2 (en) * 2004-08-06 2012-10-11 Genentech, Inc. Assays and methods using biomarkers
JP5237638B2 (ja) * 2004-08-06 2013-07-17 ジェネンテック， インコーポレイテッド バイオマーカーを用いたアッセイおよび方法
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
WO2008061377A1 (en) * 2006-11-22 2008-05-29 Centre Hospitalier De L'universite De Montreal Novel receptor for cd40l and uses thereof
GB0724532D0 (en) * 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
US20110086770A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Combinatorial Libraries Based on C-type Lectin-like Domain
EP2621514B1 (en) 2010-09-28 2016-09-21 KAHR Medical (2005) Ltd Compositions and methods for treatment of hematological malignancies
MX2013012716A (es) 2011-05-03 2014-03-21 Genentech Inc Agentes de disociacion vascular y sus usos.
WO2013037090A1 (zh) 2011-09-16 2013-03-21 北京沙东生物技术有限公司 包含trail/apo2l环化变构体的融合蛋白及其编码基因与应用
EP2684896A1 (en) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
HUE035865T2 (en) 2013-03-14 2018-05-28 Bristol Myers Squibb Co Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
US9914761B2 (en) 2014-07-10 2018-03-13 Washington University Oligomers for TNF superfamily inhibition
BR112018011100A2 (pt) 2015-12-01 2018-12-04 Genmab B.V. anticorpo, composição, construto de ácido nucleico, vetor de expressão, célula hospedeira, método para tratamento de um indivíduo que tem um câncer, kit de partes, e, uso de um anticorpo ou de uma composição.
WO2018127918A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A sirp alpha-cd70 fusion protein and methods of use thereof
WO2018127916A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A pd1-cd70 fusion protein and methods of use thereof
KR102597943B1 (ko) 2017-01-05 2023-11-06 카 메디컬 리미티드 Pd1-41bbl 융합 단백질 및 이의 이용 방법
PL3565828T3 (pl) 2017-01-05 2022-04-04 Kahr Medical Ltd. Białko fuzyjne SIRP1 ALFA-41BBL i sposoby jego zastosowania
MX2021000047A (es) 2018-07-11 2021-05-12 Kahr Medical Ltd Proteina de fusion variante pd1-4-1bbl y procedimientos de uso de la misma.
CA3104780A1 (en) 2018-07-11 2020-01-16 Kahr Medical Ltd. Sirpalpha-4-1bbl variant fusion protein and methods of use thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
IL75318A (en) 1984-05-31 1994-08-26 Genentech Inc Recombinant human memotoxin and methods for its recombinant production
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
ATE108068T1 (de) 1987-09-23 1994-07-15 Bristol Myers Squibb Co Antikörper-heterokonjugate zur töting von hiv- infizierten zellen.
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
EP0321196A3 (en) 1987-12-18 1990-07-18 Mycogen Plant Science, Inc. 780 t-dna gene transcription activator
JPH04501201A (ja) 1987-12-21 1992-03-05 ジ・アップジョン・カンパニー 発芽植物種子類のアグロバクテリウム媒介形質転換
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
ATE144793T1 (de) 1989-06-29 1996-11-15 Medarex Inc Bispezifische reagenzien für die aids-therapie
DK168302B1 (da) 1989-06-29 1994-03-07 Danisco Fremgangsmåde til indføring af molekyler, især genetisk materiale i planteceller
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
ATE131872T1 (de) 1989-11-22 1996-01-15 Genentech Inc Latenz assoziierte peptide und deren verwendung
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
EP0916678A3 (en) 1993-06-03 1999-05-26 Therapeutic Antibodies Inc. Method of clotting blood
WO1995010540A1 (en) 1993-10-14 1995-04-20 Immunex Corporation Fas antagonists and uses thereof
AU7983294A (en) 1993-10-19 1995-05-08 Regents Of The University Of Michigan, The P53-mediated apoptosis
IL111125A0 (en) 1994-05-11 1994-12-29 Yeda Res & Dev Soluble oligomeric tnf/ngf super family ligand receptors and their use
US6284236B1 (en) * 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
DE69635480T2 (de) 1995-06-29 2006-08-17 Immunex Corp., Thousand Oaks Apoptosis induzierendes cytokin
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
WO1997046686A2 (en) 1996-06-07 1997-12-11 Amgen Inc. Tumor necrosis factor-related polypeptide
KR20020056565A (ko) 2000-12-29 2002-07-10 황규언 인간유래 세포 소멸 인자와 그 수용체의 결합체인ＴＲＡＩＬ-ｓＤＲ5 결합체의 결정화에 의한 3차원 구조및 ＴＲＡＩＬ 결실 돌연변이 단백질
WO2002069995A2 (en) 2001-02-16 2002-09-12 Medical College Of Georgia Research Institute, Inc. Use of trail and antiprogestins for treating cancer

Also Published As

Publication number Publication date
DK1045906T3 (da) 2009-02-16
EP2017341A3 (en) 2009-04-08
JP2010246560A (ja) 2010-11-04
DE69939732D1 (de) 2008-11-27
CA2318029C (en) 2009-05-19
PT1045906E (pt) 2009-01-27
ATE411385T1 (de) 2008-10-15
EP2017341A2 (en) 2009-01-21
EP1045906B1 (en) 2008-10-15
WO1999036535A1 (en) 1999-07-22
CA2318029A1 (en) 1999-07-22
ES2316182T3 (es) 2009-04-01
HK1032603A1 (en) 2001-07-27
US6740739B1 (en) 2004-05-25
EP1045906A1 (en) 2000-10-25
WO1999036535A9 (en) 2000-03-02
JP2002508962A (ja) 2002-03-26
AU2325199A (en) 1999-08-02

Similar Documents

Publication Publication Date Title
CY1108681T1 (el) Συνδετης αρο-2
DE69737747D1 (de) Apo-2 ligand
EP1244465A4 (en) INDUCING CELLULAR IMMUNE RESPONSES TO ANTIGENS OF PROSTATE CANCER USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
IL148839A0 (en) April receptor (bcma) and uses thereof
DE69838249D1 (de) Anti-apo-2 antikörper
EA199800391A1 (ru) Ингибирование роста опухоли антисмысловыми олигонуклеотидами к il-8 и il-8 рецептору
IL126557A0 (en) Quinoline carboxamides as tnf inhibitors and as pde-iv inhibitors
BG101103A (bg) Теломераза при бозайници
EA199900187A1 (ru) Лиганд, родственный фактору некроза опухоли
HU9301677D0 (en) Polypeptide-type compounds of medical effect
SE9904674D0 (sv) Novel compounds
ATE414103T1 (de) Chimere tnf-liganden
DE69533873D1 (de) Krebstherapie mit lymphotoxin
DK0495910T3 (da) Fremstilling og anvendelse af humant nm23-H2-protein og derimod rettede antistoffer
ES2146243T3 (es) Inhibidores de tnf.
MXPA01010890A (es) Acidos nucleicos aislados de la familia p-hyde, proteinas p-hyde, y metodos para inducir susceptibilidad a la induccion de muerte celular en cancer.
BR9706727A (pt) Tk2- produtos basicos da catacholase tratamento de tumores (câncer).
SU1241696A1 (ru) Способ получения комплексов фталоцианина с редкоземельными элементами
ZHANG et al. Advances of the research in gene therapy for prostate cancer
DE60038020D1 (de) Vier-helix bündelprotein zsig81
UA11560A1 (uk) Тампоhажhа суміш
IT8419465A0 (it) Dispersione di carbone in acqua.
BR8304160A (pt) Forno de carbonizacao descontinuo de biomassa api
IT208523Z2 (it) Struttura di dispositivo per il trattamento con campi magnetici di acque dure.
EA199800511A1 (ru) Способ получения микроорганизмов, способных к продуцированию противоопухолевых молекул